asset – Talk Bio

GSK Secures Exclusive Rights to Syndivia’s Preclinical Prostate Cancer ADC in $357 Million Deal

5 days ago talkbio0Tagged asset, GeminiMab technology, Licensing, Malignant neoplasm of prostate, Metastatic castration-resistant prostate cancer, milestone payments, Oncology Pipeline, Preclinical, SmithKline Beecham, Syndivia, therapeutic autologous dendritic cells

GSK; Syndivia; ADC; prostate cancer; metastatic castration-resistant prostate cancer; exclusive licensing; oncology pipeline; GeminiMab technology; milestone payments; preclinical asset

AnaptysBio Announces Strategic Business Split to Create Two Public Companies, Sharpening Asset Focus

1 month ago talkbio0Tagged AnaptysBio, asset, biopharmaceutical development, business split, Immunology, Imsidolimab, Jemperli, public companies, restructuring, royalty management

AnaptysBio; business split; royalty management; biopharmaceutical development; Jemperli; imsidolimab; public companies; immunology treatments; asset value; restructuring

Lundbeck Offloads Assets to Three Partners as It Exits 27 Markets, Leaving 602 Jobless

2 months ago talkbio0Tagged asset, Exit, Lundbeck, Market, neuro-rare diseases, neuro-specialty diseases, NewBridge Pharmaceuticals, offloading, partnerships, restructuring, Swixx Group, Zuellig Pharma

Lundbeck; market exit; asset offloading; partnerships; job cuts; Swixx Group; Zuellig Pharma; NewBridge Pharmaceuticals; restructuring; neuro-rare diseases; neuro-specialty diseases

23andMe to Restart Auction After Former CEO Anne Wojcicki Outbids Regeneron

5 months ago talkbio0Tagged Anne Wojcicki, asset, auction, Bankruptcy, Regeneron, Sales - occupational activity, Science of genetics, TTAM

23andMe; auction; Anne Wojcicki; Regeneron; TTAM Research Institute; bankruptcy; asset sale; genetics

iTeos to Shut Down Operations After TIGIT Therapy Setback

5 months ago talkbio0Tagged asset, belrestotug, Clinical trial failure, ENT1, EOS-215, EOS-984, Exit, Failure (biologic function), immuno-oncology, iTeos, Obesity, Programs - Publication Format, Sales - occupational activity, SmithKline Beecham, TIGIT gene

iTeos Therapeutics; TIGIT failure; GSK exit; clinical trial failure; belrestotug; asset sale; immuno-oncology; EOS-984; EOS-215; ENT1 obesity program

Novo Nordisk Pursues $830 Million Fraud Claim Against KBP Biosciences Over Failed Hypertension Drug

9 months ago talkbio0Tagged Arbitrating, asset, Biosciences, Clinical Trials, Failure (biologic function), Fraud, Freezing, Hypertensive disease, kilobase pairs, Nordisk, Ocedurenone

Novo Nordisk, KBP Biosciences, ocedurenone, fraud, asset freeze, clinical trial failure, hypertension drug, arbitration

Relmada Acquires Promising Tourette’s Syndrome Drug Candidate from Asarina Pharma

9 months ago talkbio0Tagged Acquisition, Asarina, asset, CNS disorder, Neurosteroids, Pharma, Phase 2b, Pregnanolone, (3beta, 5alpha)-isomer, Relmada, Tourette 's syndrome

Relmada Therapeutics, Asarina Pharma, Sepranolone, Tourette’s syndrome, neurosteroid, Phase 2b, asset acquisition, CNS disorders

WuXi Biologics Divests Irish Vaccine Facility to Merck for $500 Million Amid Strategic Shift

10 months ago talkbio0Tagged asset, Biological Factors, BIOSECURE, Dundalk, Facility (object), Ireland, Merck, regulatory, Sales - occupational activity, strategic shift, Vaccines, WuXi

WuXi Biologics, Merck, vaccine manufacturing facility, Dundalk, Ireland, asset sale, strategic shift, regulatory changes, Biosecure Act

Incyte’s $750M Acquisition Hits Roadblock: Key Trial Paused and Asset Cull Announced

12 months ago talkbio0Tagged asset, cull, Drug Industry, Incyte, News [Publication Type]

Incyte, $750M buyout, paused trial, asset cull, biotech news, pharmaceutical industry

AbbVie Expands CNS Capabilities with $1.4 Billion Acquisition of Aliada Therapeutics

1 year ago talkbio0Tagged AbbVie, ALIA-1758, Aliada, Alzheimer 's disease, anti-amyloid, asset, Blood - brain barrier anatomy, CNS disorder, pharmaceutical acquisition, Study models, Technology

AbbVie, Aliada Therapeutics, CNS diseases, Alzheimer’s disease, anti-amyloid asset, blood-brain barrier technology, MODEL platform, ALIA-1758, pharmaceutical acquisition